GTHX (G1 Therapeutics) קפיטליזציה חשבונאית

G1 Therapeutics, Inc. (GTHX) enjoys a high level of trust among oncologists due to the efficacy of its solutions. The company acts as a pioneer in myeloprotection, offering Cosela, the only FDA-approved drug that protects immunity during chemotherapy. This daily price chart, where the indicator stands at 0.02, complements the profile of the US biopharmaceutical firm, which reduces treatment toxicity through a strong development pipeline.

The strategic expansion of G1 Therapeutics, Inc. (GTHX) through international licensing agreements in oncology directly impacts the company's net asset value. By analyzing the equity value dynamics on the balance sheet, an investor can observe a market revaluation of the business's real capital, stripped of speculation, which allows for an objective comparison of the company's fundamental value against current share prices on US trading venues.